Can spaxentan be used with other medications?
Sparsentan, an innovative drug developed byTravere Therapeutics, has attracted widespread attention in the medical community in recent years. As a dual endothelin-angiotensin receptor antagonist, sparsentan has achieved remarkable results in the treatment of primary immunoglobulin A nephropathy with its unique mechanism, helping to reduce proteinuria and protect renal function in patients.
However, like other medications, sparsentan may interact with other medications with consideration. Based on available research and clinical data, concomitant use of sparsentane with certain medications may result in a range of effects.
First of all, the combined use of drugs such as renin-angiotensin system inhibitors, endothelin receptor antagonists, and aliskiren with sparsentan is expressly prohibited. This is because the combination of these drugs may result in a significant increase in the risk of hypotension, which may lead to syncope, hyperkalemia, and changes in renal function, including potential acute renal failure.
In addition, sparsentan has shown specific responses when interacting with strong and moderately potentCYP3A inhibitors. Concomitant use of strong CYP3A inhibitors with sparsentane should be avoided or, if avoidance is unavoidable, treatment with sparsentane should be suspended. For moderate CYP3A inhibitors, although they can be used together, the patient's blood pressure, serum potassium, edema, and renal function need to be monitored regularly.
In addition, antacids and acid-reducing agents may affect the effectiveness of sparsentane. Because sparsentane exhibits pH-dependent solubility, when using antacids or acid-reducing agents, caution is needed as these drugs may reduce the exposure of sparsentane, thereby affecting its therapeutic efficacy.
In summary, sparsentan needs to be used with careful consideration of its interactions with other medications. In order to ensure the patient's safety and therapeutic effect, doctors will carefully evaluate the patient's medication history before issuing a prescription and formulate a reasonable treatment plan based on the specific situation.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)